Diabetes Management

Rapindra Lamichhane, MD Emily K. Flores, PharmD, BCPS

Disclosures

 Neither of us have a financial interest/arrangement or affiliation that could be perceived as a real or apparent conflict of interest related to the content or supporters of this activity.


Objectives

- List goals of care for diabetes management
- Describe a person-centered approach to diabetes management
- Provide education on foundational knowledge for patients living with diabetes




Three quarters of people with diabetes live in low and middle income countries





With all of this in mind, we must remember that ... **Diabetes belongs to the patient ...** And we can seek to provide person-centered care



DECISION (

REVIEW AND AGRE

- Review management
- Mutually agree on
- Ensure agreed mo in a timely fashior
- Undertake decision
- Operate in an inte

PROVIDE ONGOMONITORING (

- Emotional w
- Lifestyle and
- Tolerability (
- Biofeedback weight, step

GOALS OF CARE

- Prevent complications
- Optimize quality of life

T IMPACT CHOICE

goals cardiorenal protection

mode of administration)

on use

TES

n, and lifestyle choices

IMPLE

• En: mo is d

Figure 4.1—Deci

monitoring; BP, |
DSMES, diabetes self-management education and support; HF, heart failure.


M, blood glucose vascular disease;

ASSESS KEY PERSON CHARACTERISTICS

- The individual's priorities
- Current lifestyle and health behaviors
- Comorbidities (i.e., CVD, CKD, HF)
- Clinical characteristics (i.e., age, A1C, weight)
- Issues such as motivation, depression, cognition
- Social determinants of health

Are they using any plant medicines?

CONSIDER SPECIFIC FACTORS THAT IMPACT CHOICE OF TREATMENT Individualized glycemic and weight goals Impact on weight, hypoglycemia, and cardiorenal protection Underlying physiological factors tions Side effect profiles of medications f life Complexity of regimen (i.e., frequency, mode of administration) Regimen choice to optimize medication use and reduce treatment discontinuation



UTILIZE SHARED DECISION-MAKING TO CREATE A MANAGEMENT PLAN

- Ensure access to DSMES
- Involve an educated and informed person (and the individual's family/caregiver)
- Explore personal preferences
- Language matters (include person-first, strengths-based, empowering language)
- Include motivational interviewing, goal setting, and shared decision-making

AGREE ON MANAGEMENT PLAN

- Specify SMART goals:
 - **S**pecific
 - Measurable
 - Achievable
 - Realistic
 - Time limited

IMPLEMENT MANAGEMENT PLAN

 Ensure there is regular review; more frequent contact initially is often desirable for DSMES

REVIEW AND AGREE ON MANAGEMENT PLAN

- Review management plan
- Mutually agree on changes
- Ensure agreed modification of therapy is implemented in a timely fashion to avoid therapeutic inertia
- Undertake decision cycle regularly (at least once/twice a year)
- Operate in an integrated system of care

PROVIDE ONGOING SUPPORT AND MONITORING OF:

- Emotional well-being
- Lifestyle and health behaviors
- Tolerability of medications
- Biofeedback including BGM/CGM, weight, step count, A1C, BP, lipids

Person-centered approach in steps

- 1. Assess key person characteristics
- 2. Consider specific factors that impact choice of treatment
- 3. Utilize shared decision-making to create a management plan
- 4. Agree on management plan
- 5.Implement management plan
- 6.Review and agree on management plan
- 7. Provide ongoing support and monitoring

GOALS OF CARE

- Prevent complications
- Optimize quality of life

GOALS OF CARE

- Prevent complications
- Optimize quality of life




Foundational knowledge


- 1. What is diabetes?
- 2. Complication risk & prevention
- 3. Nutrition
- 4. Exercise
- 5. Medications
- 6. Monitoring
- 7. Low blood sugar management
- 8. Support

What is diabetes?
















1


The sugar (glucose) contained in food is absorbed into the blood-stream and carried to the liver, and then half of it is transported to the entire body.



The pancreas releases insulin in reaction to the increase of sugar in the blood


Insulin transports glucose to cells throughout the body that absorb and use it. Glucose can also be stored by insulin.

Blood sugar level then drops




Glucose is absorbed into cells that make up muscle, the liver, fats, etc. **Complication risk & prevention**

What part of comprehensive care & complication prevention can a variety of interprofessional team members help with?



Nutrition



How can patients work through cost or access challenges?

https://institute.org/health-care/services/diabetescare/healthyplates/

My Healthy Plate



best drink for you.

Vegetables

 $\frac{1}{1}$

Plan the portions on your plate.



Ask your nutritionist if you should eat fruit or dairy











Medications









		Efficacy ¹	Hypogly-	Weight change ²	CV ef	fects		Renal effects	Oral/SQ	Cost	Clinical considerations
		Ellicacy	cemia	weight change	Effect on MACE	HF	Progression of DKD	Dosing/use considerations*	UIAU'SU	Cust	Clinical Considerations
Metforn	nin	High	No	Neutral (potential for modest loss)	Potential benefit	Neutral	Neutral	Contraindicated with eGFR <30 mL/min per 1.73 m ²	Oral	Low	GI side effects common; to mitigate GI side effects, consider slow dose titration, extended release formulations, and administration with food Potential for vitamin B12 deficiency; monitor at regular intervals
Sulfony (2nd ge	lureas neration)	High	Yes	Gain	Neutral	Neutral	Neutral	Glyburide: generally not recommended in chronic kidney disease Glipizide and glimepiride: initiate conservatively to avoid hypoglycemia	Oral	Low	FDA Special Warning on increased risk of CV mortality based on studies of an older sulfonylurea (tolbutamide); glimepiride shown to be CV safe (see text) Use with caution in persons at risk for hypoglycemia
Insulin	Human	High to	Yes	Gain	Neutral	Neutral	Neutral	Lower insulin doses required with a	SQ; inhaled	Low (SQ)	Injection site reactions
	Analogs	very high						decrease in eGFR; titrate per clinical response	SQ	High	Higher risk of hypoglycemia with human insulin (NPH or premixed formulations) vs. analogs

Plant Medicines

- Used by 85.7% of patients with T2DM
- Only 1 out of 30 disclose use to providers
- Benefits
 - Cultural safety
 - Locally accessible
 - Low cost
- Risks
 - Lack of disclosure
 - Unknown interactions or adverse effects





Table 2. Plants found in Belize that are used for type 2 diabetes self-management.

Common name	Scientific name	Part used	
Aloe vera	Aloe socotrina	leaf	
Aloe vera	Aloe barbadensis	leaf	
Bitterbark	Alstonia constricta	bark	
Cinnamon	Cinnamomum zeylanicum	bark	
Coconut	Cocos nucifera	nut, meat, milk	
Fever grass	Cymbopogon densiflorus	leaf	
Ginger	Zingiber officinale	root	
Gumbolimbo	Bursera simaruba	bark, leaf	
Jackass bitters	Neurolaena lobata	leaf, root	
Lime	Citrus aurantifolia	leaf, seed	
Mango	Mangifera indica	bark, leaf	
Moringa	Moringa oleifera	leaf	
Neem	Azadirachta indica	bark, leaf	
Noni	Morinda citrifolia	leaf, root	
Oil nut	Ricinus communis	leaf, seed	
Okra	Abelmoschus esculentus	leaf, seed	
Papaya	Carica papaya	fruit, leaf, seed, root	
Sage	Salvia officinalis	leaf	
Sour sop	Annona muricata	fruit, leaf	
Tumeric	Curcuma longa	root	
Vervain	Verbana hastat	leaf	
Vervain	Stachytarpheta jamaicensis	leaf	


Metformin

- Benefits
 - 1-2% A1c reduction
 - Morbidity/mortality benefits
- Risks
 - Gastrointestinal side effects
 - Vitamin B12 deficiency longterm
 - Contraindicated < 30 mL/min eGFR




Glibenclamide

- Benefits
 - 1-2% A1c reduction
- Risks
 - Weight gain
 - Hypoglycemia
 - No morbidity/mortality
 - Secondary failure
 - Renal accumulation




Insulin

- Benefits
 - 1-2% A1c reduction
 - Right regimen can get to goal
- Risks
 - Weight gain
 - Hypoglycemia
 - No morbidity/mortality
 - Injectable
 - Requires SMBG
 - Storage







Isophane

- Basal
- Cloudy

Soluble

- Bolus
- Clear

70/30

- Both
- Cloudy

Others

- Analog insulin
- SGLT2 inhibitor (Empagliflozin, etc.)
- GLP-1 receptor agonist (Dulaglutide, etc.)
- GDIP and GLP-1 RA combination (Tirzepatide, etc.)
- DPP-IV inhibitors (Sitagliptin, etc.)
- Thiazolidinediones (Pioglitazone)
- Alpha glucosidase inhibitor (Acarbose, etc.)

- Home glucose monitoring by fingerstick
- Continuous glucose monitoring (CGM)
- Continuous subcutaneous insulin infusion ("insulin pump")
- Even more others now, historically, or to come ...



Risks

Monitoring




Low blood sugar management

RULE OF 15

FOR TREATING LOW BLOOD SUGAR

Your **blood sugar may be LOW** if you feel shaky, dizzy, hungry, anxious, irritable or have a fast heartbeat, blurry vision, or headache.



If after steps 1234 you blood sugar reading is **STILL NOT** in NORMAL RANGE, then *repeat* steps 2 EAT 15 WAIT 154 CHECK.

Support







GOALS OF CARE

- Prevent complications
- Optimize quality of life



Knowledge is a rare thing you gain by giving it away. Ivan Sutherland (ff) quotefancy

Diabetes Management

Rapindra Lamicchane, MD lamichhaner@etsu.edu

Emily K. Flores, PharmD, BCPS florese@etsu.edu